

ImmunogenX Receives a Tibbetts Award

The Small Business Administration (SBA) announces an individual and company award for excellence in the Small Business Innovation Research (SBIR) program

The U.S. SBA announced 38 companies, seven organizations and 14 individuals as the winners of the prestigious Tibbetts Award for their accomplishments in creating cutting-edge technologies. The Tibbetts Awards, named after Roland Tibbetts, the founder of the SBIR Program, honors these awardees for the exceptional successes they achieved through SBA's SBIR program. An individual award was given to Jack Syage PhD, CEO of ImmunogenX for his lifetime of commercializing SBIR grants at Syagen Technology and currently at ImmunogenX. Only three individual awards were made this year to entrepreneurs. The company was also awarded a Tibbetts for its very successful application of three National Institutes of Health (NIH) grants, each funding Phase 2 clinical trials for the company's therapeutic candidate latiglutenase for the treatment of celiac disease (CD).

"For nearly four decades, the SBIR and STTR programs have been assisting small businesses with launching ideas from conception to market. The Tibbetts Awards highlight our nation's next generation of competitive creators who help push the U.S. economy into the future," said SBA Administrator Jovita Carranza.

Jack Syage comments, "We are proud to be recognized for our broad commercial success made possible by the U.S. government's trust and investment in us through the SBIR program. We are continuing to make these SBIR investments very worthwhile through the grants we have received from the NIH to help support our final Phase 2 clinical trials for latiglutenase."

The company and individual awards can be viewed on <https://www.tibbettsawards.com/immunogenx/> and <https://www.tibbettsawards.com/jack-syage/>.

About ImmunogenX

ImmunogenX, Inc. is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel[™]) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye.

www.immunogenx.com

For further information please contact

Matthew Dickason, MBA
Chief Operating Officer
949 679-0900
mdickason@immunogenx.com